- Remove All
Your shopping cart is currently empty
Butyrophilin-Like Protein 9 (BTNL9) is single-pass type I membrane protein member of the BTN/MOG family that belongs to the immunoglobulin superfamily. BTNL9 consists of two domains: one B30.2/SPRY domain and one Ig-like V-type (immunoglobulin-like) domain. Human BTNL9 mRNA has been identified in adipose, lung, thymus, spleen, colon, and cardiac tissues, but its highest levels of expression were found in B cells. BTNL9 expression has also been found to be down-regulated in colon cancer tumors. BTNL9 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 18-30 KDa and the accession number is Q6UXG8.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 μg | $58 | 7-10 days | |
| 10 μg | $91 | 7-10 days | |
| 20 μg | $129 | 7-10 days | |
| 50 μg | $215 | 7-10 days | |
| 100 μg | $343 | 7-10 days | |
| 200 μg | $552 | 7-10 days | |
| 500 μg | $1,030 | 7-10 days | |
| 1 mg | $1,490 | 7-10 days |
| Biological Activity | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| Description | Butyrophilin-Like Protein 9 (BTNL9) is single-pass type I membrane protein member of the BTN/MOG family that belongs to the immunoglobulin superfamily. BTNL9 consists of two domains: one B30.2/SPRY domain and one Ig-like V-type (immunoglobulin-like) domain. Human BTNL9 mRNA has been identified in adipose, lung, thymus, spleen, colon, and cardiac tissues, but its highest levels of expression were found in B cells. BTNL9 expression has also been found to be down-regulated in colon cancer tumors. BTNL9 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 18-30 KDa and the accession number is Q6UXG8. |
| Species | Human |
| Expression System | HEK293 Cells |
| Tag | C-6xHis |
| Accession Number | Q6UXG8 |
| Synonyms | Butyrophilin-like protein 9,BTNL9 |
| Amino Acid | Glu48-Ser160 |
| Construction | Glu48-Ser160 |
| Molecular Weight | 18-30 KDa (reducing condition) |
| Endotoxin | < 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH7.4. |
| Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| Stability & Storage | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| Research Background | Butyrophilin-Like Protein 9 (BTNL9) is single-pass type I membrane protein member of the BTN/MOG family that belongs to the immunoglobulin superfamily. BTNL9 consists of two domains: one B30.2/SPRY domain and one Ig-like V-type (immunoglobulin-like) domain. Human BTNL9 mRNA has been identified in adipose, lung, thymus, spleen, colon, and cardiac tissues, but its highest levels of expression were found in B cells. BTNL9 expression has also been found to be down-regulated in colon cancer tumors. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.